Citigroup
DSGN icon

Citigroup’s Design Therapeutics DSGN Stock Holding History

Citigroup’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$230K Buy
15,880
+11,617
+273% +$145K ﹤0.01% 4270
2026
Q1 		$45.4K Buy
4,263
+1,150
+37% +$11.6K ﹤0.01% 4559
2025
Q4 		$29.2K Buy
3,113
+1,523
+96% +$11.9K ﹤0.01% 4761
2025
Q3 		$12K Sell
1,590
-12,058
-88% -$60.4K ﹤0.01% 4963
2025
Q2 		$46K Sell
13,648
-9,231
-40% -$34.5K ﹤0.01% 4804
2025
Q1 		$88.3K Sell
22,879
-1,597
-7% -$7.62K ﹤0.01% 4668
2024
Q4 		$151K Buy
24,476
+1,331
+6% +$7.71K ﹤0.01% 4608
2024
Q3 		$125K Buy
23,145
+15,911
+220% +$74.8K ﹤0.01% 4659
2024
Q2 		$24.2K Buy
7,234
+905
+14% +$3.53K ﹤0.01% 4944
2024
Q1 		$25.5K Buy
6,329
+1,514
+31% +$4.04K ﹤0.01% 4955
2023
Q4 		$12.8K Buy
4,815
+4,041
+522% +$9.26K ﹤0.01% 5134
2023
Q3 		$1.83K Sell
774
-9,942
-93% -$46.4K ﹤0.01% 4985
2023
Q2 		$67.5K Buy
10,716
+7,309
+215% +$44.7K ﹤0.01% 4463
2023
Q1 		$19.7K Sell
3,407
-106,253
-97% -$795K ﹤0.01% 4520
2022
Q4 		$1.13M Buy
109,660
+75,393
+220% +$1.02M ﹤0.01% 2512
2022
Q3 		$573K Buy
34,267
+25,753
+302% +$512K ﹤0.01% 3140
2022
Q2 		$119K Sell
8,514
-10,208
-55% -$138K ﹤0.01% 4133
2022
Q1 		$302K Sell
18,722
-9,477
-34% -$145K ﹤0.01% 3838
2021
Q4 		$604K Buy
28,199
+3,391
+14% +$58.2K ﹤0.01% 3657
2021
Q3 		$364K Buy
24,808
+1,118
+5% +$18.6K ﹤0.01% 3828
2021
Q2 		$471K Buy
+23,690
New +$598K ﹤0.01% 3753

Other funds holding DSGN

SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Citigroup's DSGN Position: Q2 2026 in Review

Citigroup increased its Design Therapeutics (DSGN) stake by 273% in Q2 2026, buying an estimated $145K and bringing the position to 15,880 shares worth $230K. The position accounts for ﹤0.01% of the portfolio, ranked #4270.

Citigroup first reported a position in DSGN in Q2 2021 and has held it in 21 quarters since. The position peaked at $1.13M in Q4 2022. 136 funds tracked by Wall St. Rank hold DSGN as of Q2 2026.

  • Citigroup held 15,880 shares of Design Therapeutics worth $230K as of Q2 2026.
  • Citigroup bought 11,617 Design Therapeutics shares in Q2 2026, an estimated $145K.
  • Design Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #4270 holding.
  • Citigroup first reported a position in Design Therapeutics in Q2 2021 and has held it in 21 quarters since.
  • Citigroup's Design Therapeutics position peaked at $1.13M in Q4 2022.
  • 136 funds tracked by Wall St. Rank held Design Therapeutics as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.